pharmaphorum

JUNE 26, 2025

US biotech Vor Bio has turned to Chinas RemeGen to revitalise its pipeline, paying $125 million upfront for rights to a drug already approved in its home market for multiple autoimmune diseases. In a phase 3 gMG trial carried out in China, telitacicept showed a 4.8-point

Licensing

Pharmaceutical Technology

JUNE 19, 2025

Can pharma tariffs “Make America Manufacture Again”? King said: “Manufacturing drugs in space sounds like sci-fi – but the time is now. Crystallisation is a process that is better in space compared to on Earth, and that’s because gravity inhibits that process.

Clinical Trials

Pharmaceutical Technology

JUNE 18, 2025

Can pharma tariffs “Make America Manufacture Again”? June 18, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook GATC’s MAT platform identifies potential new drugs and provides comprehensive analytic reports. Credit: Viacheslav Lopatin/Shutterstock. Credit: Viacheslav Lopatin/Shutterstock.

Development

Bio Pharma Dive

JUNE 23, 2025

Originally developed in the 1970s to treat diabetes, these drugs—such as Ozempic, Wegovy, and Mounjaro—have become headline-makers for their ability to induce significant weight loss. Understanding GLP-1 drugs GLP-1, or glucagon-like peptide-1 receptor modulators, mimic natural hormones that regulate insulin and appetite.

Gene Therapy

Pharmaceutical Technology

JUNE 24, 2025

Can pharma tariffs “Make America Manufacture Again”? In the Research & Development category, i3 Membrane was honored for its efforts to scale DMC for commercial therapeutic drug manufacturing, demonstrating superior performance and efficiency.

Manufacturing

Pharmaceutical Technology

JUNE 25, 2025

Can pharma tariffs “Make America Manufacture Again”? Fresh off a regulatory victory for a new HIV product, Gilead is shifting focus to the oncology space – signing a deal worth up to $750m to license a solid tumour treatment candidate from Kymera Therapeutics. Credit: Sundry Photography via Shutterstock.

Drugs

Pharmaceutical Technology

JUNE 19, 2025

Can pharma tariffs “Make America Manufacture Again”? In a final blow to Eli Lilly’s Kisunla (donanemab) and Eisai’s Leqembi (lecanemab) UK reimbursement prospects, the National Institute for Health and Care Excellence (NICE) has decided against recommending the two Alzheimer’s drugs for NHS use.

Drugs

Pharmaceutical Technology

JUNE 25, 2025

Can pharma tariffs “Make America Manufacture Again”? Biopharmaceutical companies developing Alzheimer’s disease innovator drugs have witnessed a flurry of acquisitions over the past few years, surging in total deal value by more than 780% from $2 billion in 2022 to almost $18 billion in 2024. Credit: JLStock via Shutterstock.

Clinical Trials

Pharmaceutical Technology

JULY 28, 2025

EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Find out more GSK will pay an upfront fee of $500m, which includes licensing for the phosphodiesterase (PDE)3/4 programme.

Clinical Trials

Pharmaceutical Technology

JULY 22, 2025

EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? The latest manufacturing investment will support the ongoing development of Biogen’s late-stage clinical pipeline.

Research

Pharmaceutical Technology

JUNE 12, 2025

Can pharma tariffs “Make America Manufacture Again”? Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m partnership with Deep Apple Therapeutics to access novel compounds for obesity and other diseases.

Research

Pharmaceutical Technology

JUNE 26, 2025

Can pharma tariffs “Make America Manufacture Again”? A month and a half after winding operations and laying off almost all its staff, Vor Bio has emerged from the brink with a licensing deal potentially rising to $4bn for an autoimmune drug developed by Chinese biotech RemeGen.

Drugs

Pharmaceutical Technology

JUNE 19, 2025

Can pharma tariffs “Make America Manufacture Again”? Thank you for subscribing View all newsletters from across the GlobalData Media network.

Clinical Trials

XTalks

JULY 10, 2025

Potency assays play a vital role in biopharmaceutical development by measuring a drug candidate’s biological activity against a reference standard — offering essential insights into product quality and its potential clinical success. Dr. Erika Kovacs Sr. In early development, they support candidate selection and help optimize formulations.

Bioassay

Pharmaceutical Technology

JULY 21, 2025

EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? The rapid advancement of AI-powered tools, such as RoseTTAFold and AlphaFold, has revolutionised protein structure prediction, creating exciting opportunities across drug discovery and structural biology.

Protein

Pharmaceutical Technology

JUNE 18, 2025

Can pharma tariffs “Make America Manufacture Again”? Donnelly commented: “A big part of our business in genomics is helping pharma companies and biotechs on their drug discovery journey, and part of that is using genetics upstream to help them find better drug targets.

Genomics

Bio Pharma Dive

JULY 22, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief // Vaccines Sanofi to acquire vaccine biotech in billion-dollar deal The French pharma will pay $1.15 You can unsubscribe at anytime.

Vaccination

Pharmaceutical Technology

JUNE 20, 2025

Can pharma tariffs “Make America Manufacture Again”? June 20, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The MoU was signed at the BIO International Convention 2025 in Boston, US. Credit: Department of Health Abu Dhabi.

Vaccination

Pharmaceutical Technology

JUNE 6, 2025

Can pharma tariffs “Make America Manufacture Again”? wants to ensure the ensuing the US does not lag behind other countries in drug development. We are going to make this country the hub of biotechnology innovation,” RFK Jr said during a US Food and Drug Administration (FDA) roundtable on cell and gene therapy on 5 June.

Regulation

Pharmaceutical Technology

JUNE 23, 2025

Can pharma tariffs “Make America Manufacture Again”? Otsuka will receive exclusive global rights to develop, manufacture and commercialise HBM7020 outside Greater China.

Gene Therapy

Pharmaceutical Technology

JUNE 12, 2025

Can pharma tariffs “Make America Manufacture Again”? Finally, vutrisiran’s launch in the ATTR-CM market will be an opportunity for its manufacturer, Alnylam, to potentially increase sales, as ATTR-wt patient numbers continue growing. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

Clinical Trials

The Pharma Data

JUNE 24, 2025

The partnership represents a major financial and strategic milestone for Revolution Medicines, which has built a robust pipeline of targeted therapies aimed at cancers driven by mutations in the RAS family of genes—some of the most prevalent and historically difficult-to-drug oncogenes in human cancer.

Medicine

Pharmaceutical Technology

JUNE 18, 2025

Can pharma tariffs “Make America Manufacture Again”? Tisento Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its investigational oral medicine, zagociguat, for mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), a rare mitochondrial disease.

Clinical Trials

Pharmaceutical Technology

JUNE 25, 2025

Can pharma tariffs “Make America Manufacture Again”? The US Food and Drug Administration (FDA) has expanded the indications of an imaging agent developed by GE HealthCare, which will likely put it at the forefront of the Alzheimer’s diagnostics arena. Credit: Utthapon wiratepsupon via Shutterstock.

Clinical Trials

Pharmaceutical Technology

JULY 24, 2025

EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Give your business an edge with our leading industry insights.

Clinical Trials

Pharmaceutical Technology

JUNE 12, 2025

Can pharma tariffs “Make America Manufacture Again”? SB-007 has received clearance from the Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) to enter clinical development. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? “The

Gene Therapy

Pharmaceutical Technology

JULY 28, 2025

EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Thank you for subscribing View all newsletters from across the GlobalData Media network.

Marketing

Pharmaceutical Technology

JUNE 25, 2025

Can pharma tariffs “Make America Manufacture Again”? GlobalData Healthcare June 25, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Changes to ACIP could result in regulatory uncertainty for vaccine developers and manufacturers. Credit: Melnikov Dimitriy via Shutterstock.

Vaccination

Drug Patent Watch

DECEMBER 18, 2024

Drug patent prosecution is a complex and critical process that can make or break the success of a new medication. As a business professional in the pharmaceutical industry, understanding and implementing effective strategies for drug patent prosecution can be the difference between market domination and missed opportunities.

Drugs

Pharmaceutical Technology

JUNE 10, 2025

Can pharma tariffs “Make America Manufacture Again”? Thank you for subscribing View all newsletters from across the GlobalData Media network.

Clinical Trials

Pharmaceutical Technology

JUNE 19, 2025

Can pharma tariffs “Make America Manufacture Again”? The US Food and Drug Administration (FDA) has awarded ABS-1230 both orphan drug and rare paediatric designations. The US regulator has granted orphan drug, fast track and rare paediatric drug designations to the therapy.

Clinical Trials

Pharmaceutical Technology

JULY 28, 2025

EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Give your business an edge with our leading industry insights.

Research

The Pharma Data

JUNE 16, 2025

This collaboration marks a significant step forward in global oncology drug development. Fosun Pharma is granted an exclusive license to develop, manufacture, and commercialize TEV-56278 in Chinese mainland, Hong Kong Special Administrative Region (SAR), Macau SAR, Taiwan, and select Southeast Asian countries.

Development

Pharmaceutical Technology

JUNE 23, 2025

Can pharma tariffs “Make America Manufacture Again”? Thank you for subscribing View all newsletters from across the GlobalData Media network.

Manufacturing

Pharmaceutical Technology

JULY 22, 2025

EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Icotrokinra was co-discovered and is currently being developed through a licensing and collaboration agreement between Protagonist and J&J.

FDA Approval

Pharmaceutical Technology

JUNE 12, 2025

Can pharma tariffs “Make America Manufacture Again”? Thank you for subscribing View all newsletters from across the GlobalData Media network.

Clinical Trials

XTalks

JUNE 25, 2025

Administered subcutaneously every six months, lenacapavir forms a slow-release depot that maintains protective drug levels in the body, effectively blocking infection. To address global access concerns, Gilead has announced a series of licensing and pricing initiatives.

FDA Approval